Accuity vs SmarterDx
Two Revenue Integrity & Pre-Bill Review vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Accuity | SmarterDx | |
|---|---|---|
| Pricing model | Contingency (pay from recoveries) · 60-day pilot, no upfront fees | Contingency (pay from recoveries) · paid only from net new revenue |
| Speed to go live | Chart data feed plus 60-day pilot | weeks, sidecar to existing coding workflow |
| Automation model | Tech-enabled service · AI triage, physician-performed reviews | Software platform · AI prebill review, human in loop |
| Built for | Enterprise systems | Enterprise systems |
| Security posture | HITRUST | SOC 2 Type II, HIPAA |
| Company maturity | 10 yrs (est. 2016) | 6 yrs (est. 2020) |
| Financial backing | Undisclosed | PE-backed (Smarter Technologies, a New Mountain Capital platform) |
| Named customers | 1 named | 3 named |
| Published results | Specific numbers public | Specific numbers public |
| Documented integrations | None documented | 3 listed |
| Third-party validation | None found | KLAS / analyst cited |
Bottom line
- Pick Accuity if you want guaranteed inpatient revenue capture from a physician-staffed service rather than another tool for your own team.
- Pick SmarterDx if you are a hospital that wants found revenue from every chart with no upfront budget or workflow change.
Accuity
Physician-led pre-bill chart review that recovers earned revenue
- Founded
- 2016
- HQ
- Mount Laurel, NJ
- Stage
- n/a
- Raised
- n/a
What it does
- Post-discharge, pre-bill second-level chart review
- Amplifi AI trained on 7M+ chart outcomes
- 185 multi-specialty physicians review flagged cases
- DRG, CC/MCC, and quality metric capture
- Medicaid expertise across 38 states
- Compliance oversight with 1.5% final denial rate
Where it's strong
- Runs after your CDI and coding teams finish, so it adds a safety net without changing their workflow.
- Scale is proven: 400+ hospital sites, 4 of the top 10 US health systems, and $3.3B in client revenue lift.
- Performance-based pricing with a 60-day pilot and no upfront fees keeps buyer risk low.
What buyers should weigh
- It is a service engagement, not software your team operates, so capability does not transfer in-house.
- Fees come out of recovered revenue, which costs more at scale than licensing a tool.
- Focused on inpatient pre-bill review; it does not address front-end or denial workflows.
Named customers
Temple Health
SmarterDx
Pre-bill AI review that finds missed revenue and quality
- Founded
- 2020
- HQ
- New York, NY
- Stage
- PE-backed (Smarter Technologies, a New Mountain Capital platform)
- Raised
- $71M
What it does
- Reviews 100% of inpatient charts pre-bill
- Finds missed diagnoses, DRG shifts, and CC/MCC capture
- Generates AI-drafted appeals for clinical denials
- SmarterNotes ties note generation to revenue cycle intelligence
- Shows clinical evidence trail for every recommendation
Where it's strong
- Physician-founded pre-bill engine with audited results: roughly $2M net new revenue per 10,000 discharges, a 98 KLAS satisfaction score, and reported 100% client retention.
- Reviews every discharge rather than a sample, which is what makes the second-look economics work.
- New Mountain Capital backing pairs it with Access Healthcare's services scale inside Smarter Technologies.
What buyers should weigh
- Now part of a PE roll-up (merged with Access Healthcare and Thoughtful.ai in May 2025), so expect cross-sell pressure and possible roadmap shifts toward the combined platform.
- Value is concentrated in inpatient DRG reimbursement; ambulatory-heavy or critical-access organizations will see less benefit.
- It functions as a second-look layer on top of your existing CDI team and tech, an added cost line rather than a replacement.
Named customers
Novant Health · McLaren Health Care · UAMS
Integrations
Compare against the rest of Revenue Integrity & Pre-Bill Review
Deciding between these two?
First Pass tracks Revenue Integrity & Pre-Bill Review every week: funding, launches, and what changed since this page was written.